1651
clinical study

Introducing Artificial Intelligence Applications at Our Community Hospital: A Contrarian Approach

The Problem

With artificial intelligence (AI), the challenge was which applications should be introduced first to get all the stakeholders (health system administrators, patients, clinicians and radiologists) interested in the AI culture and maintain their enthusiastic support

The Solution

We found three FDA-cleared AI solutions available in the marketplace that aligned with three clinical situations we wanted to improve. These included long acquisition time for PET/CT & MRI scans, and long wait times for the radiologist’s report on critical CT findings.

Outcomes and Limitations

AI for flagging the emergency department cases for ICH, PE, and LVO was introduced. Three months of validation of the AI software took place, with false-negative rate as the primary method of validation. No false-negative cases were found during the validation phase. A very small subdural ICH identified by the AI software may have been missed by the radiologist. The accuracy of the algorithms for PE and LVO is extremely high, and AI excels in identifying PE in the small vessels.

Conclusions

Relatively small subdural ICH identified by the AI software may have been missed by the radiologist.  The accuracy of the algorithms for PE and LVO is extremely high, and AI excels in identifying PE in the small vessels.

Explore the Latest AI Insights, Trends and Research

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>

Laci Costa

<p>Laci Costa is the Director of Neurovascular Product Marketing at Aidoc. She leads marketing and commercial strategy for the neuro AI portfolio of products. She has 16 years of experience working in the medical device and healthcare industry, with over 12 years dedicated to neurovascular solutions.</p> <p>Costa’s known for her expertise in the neurovascular industry, go-to-market experience with new technologies and upstream and downstream product marketing leadership. She’s held various leadership positions in product marketing, clinical education and professional affairs spanning across start-up organizations to large publicly traded companies.</p> <p>Costa holds a bachelor’s degree in psychology from the University of Oklahoma and an MBA from USC Marshall School of Business.</p>